Leadership
Our leadership has over 200 years of collective diagnostics industry experience.
We have created a dynamic environment and culture where our team members, our executive leadership team, the Board of Directors and the Advisory Board seek to challenge and align company strategies to deliver maximum value for all stakeholders.
EXECUTIVE LEADERSHIP
MBA, CEOElise Wilfinger2023-02-27T14:48:37+00:00
James McCullough has served as our co-founder and Chief Executive Officer since our inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.
CTOElise Wilfinger2023-11-13T17:12:57+00:00
Fergus Fleming has served as our Chief Technology Officer since our inception. Mr. Fleming has served as managing director of FF Consulting Limited, providing Product Development and Commercialization support to Medical Devices and Diagnostics companies since June 2013. Roles in this period include Head of Business Development for Oncomark Limited from November 2016 to October 2018 and from 2013, he served in various roles at EKF Diagnostics plc. He has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.
PresidentGraham Dyer2024-06-24T13:03:27+00:00
Howard Doran served as our Chief Business Officer from September 2023 – April 2024. He has now assumed the role of President, with responsibility for global sales and marketing. Prior to joining Renalytix, he was President and Chief Executive Officer at LipoScience, where he stayed until its successful acquisition by LabCorp. Mr. Doran also served as President and Chief Operating Officer at Constitution Medical, Inc. and President of Hologic’s global diagnostics business. Earlier in his career, he was on the management team of Cytyc Corporation, holding a number of senior commercial roles, including physician sales and marketing, managed care, and laboratory sales and marketing. Mr. Doran received his B.S. degree in Management from West Chester University of Pennsylvania.
MBA, Interim CFOElise Wilfinger2024-06-23T19:06:58+00:00
Joel R. Jung joined Renalytix as interim Chief Financial Officer in May 2024. From 2008 – 2020, he also served as CFO for various life sciences, biotech, and diagnostic companies, including Celera Corporation, Agraquest, Inc., BioNano Genomics, and Counsyl, Inc. Most recently, he was Chief Financial Officer at Minerva Surgical, a commercial-stage medical device company. He received his BS in Aeronautical and Astronautical Engineering from Purdue University and his MBA in Finance from the Haas School of Business at the University of California, Berkeley.
PhD, MDElise Wilfinger2023-11-13T17:13:59+00:00
Michael J. Donovan, Ph.D., M.D. has served as our Chief Medical Officer since our inception. Since November 2011, Donovan has also served as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mount Sinai. In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan received a B.S. in Zoology, an M.S. in Endocrinology and a Ph.D. in Cell and Developmental Biology from Rutgers University. He received his M.D. from the University of Medicine and Dentistry of New Jersey.
Executive ChairmanGraham Dyer2024-11-06T05:26:58+00:00
Julian Baines rejoined the executive team at EKF Diagnostics Holdings plc (“EKF”) as Executive Chairman on a short term basis as announced in early February 2023. Julian is also currently Non-Executive Chairman of Verici Dx plc. Julian has significant experience in the life science industry. He has over 20 years’ experience as CEO of EKF and BBI Holdings plc. Before joining EKF, he undertook a management buyout at BBI in 2000, a flotation on AIM in 2004 and was responsible for selling the business to Alere Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million. Whilst CEO at EKF he successfully completed a number of fund raisings, acquisitions and subsequent integration of businesses in seven countries. He oversaw the spin out of businesses from EKF including Renalytix plc which listed on Nasdaq in 2020. In 2016 he was awarded an MBE (Member of the British Empire) for services to the life sciences industry. Julian has previously held the position of Non-Executive Chairman of Renalytix Plc between 2018 and 2020.
NON-EXECUTIVE DIRECTORS
Christopher Mills has served as a member of our board of directors since our inception. Mr. Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management, which he co-founded in 1993. He is chief executive officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and chairman and chief executive officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.
PhDElise Wilfinger2023-02-27T14:54:48+00:00
Erik Lium, Ph.D. has served as a member of our board of directors since November 2018. Since March 2014, Dr. Lium has served in various roles at Mount Sinai, where he is currently the president of Mount Sinai Innovation Partners, and the executive vice president and chief commercial innovation officer of the Mount Sinai Health System. Dr. Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Dr. Lium also serves as chairman of the board of managers of Kantaro. Prior to joining Mount Sinai, Dr. Lium served as the assistant vice chancellor of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF), the UCSF principal investigator for the Bay Area National Science Foundation I-Corps node, and assistant vice chancellor of Research. Dr. Lium served as president of LabVelocity Inc. prior to its acquisition in 2004. He pursued postdoctoral research at UCSF in the laboratory of J. Michael Bishop, M.D., earned a Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein, and holds a B.S. in Biology from Gonzaga University.
Catherine Coste was appointed to the Company’s Board of Directors in June 2023. Ms. Coste retired from Deloitte and Touche LLP (“Deloitte”) in 2020, where she was a Senior Partner, and served as one of Deloitte’s Life Sciences industry executive leaders. She spent 32 years in both corporate and professional services positions leading global finance, internal audit, and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. She also serves as a Director at both Minerva Surgical, Inc., where she is Chair of the Audit Committee and a Member of the Compensation Committee, and Biomerica, Inc., where she is Chair of the Audit Committee, and serves on both the Compensation Committee and the Nominating and Corporate Governance Committee. Ms. Coste’s experience includes, but is not limited to, Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. She is a Certified Public Accountant, who earned her B.A. in business administration, accounting, from California State University, Hayward.
COMPANY SECRETARY
FCAElise Wilfinger2024-11-06T18:54:18+00:00
Salim Hamir is a Chartered Accountant with extensive leadership experience across public, private, and charitable organizations. He has held pivotal roles at companies such as EKF Diagnostics Holdings, Poolbeg Pharma, Renalytix, Verici Dx, and Trellus Health. As an accomplished CFO, Finance Director, and Company Secretary, Salim brings hands-on expertise in M&A, fundraising, public listings, EIS/VCT, taxation, IFRS reporting, spin-outs, investor relations, restructurings, and corporate governance. His operational involvement has been instrumental in driving the strategic growth and success of companies he has been involved.
ADVISORS
Stifel Nicolaus Europe Limited
150 Cheapside
London
EC2V 6ET
Oberon Investments
Nightingale House
65 Curzon Street
London, W1J 8PE
Stifel Nicolaus Europe Limited
150 Cheapside
London
EC2V 6ET
Shoosmiths LLP
1 Bow Churchyard
London
EC4M 9DQ
Stevens and Lee
1500 Market Street, East Tower, 18th Floor
Philadelphia, PA 19102
PKF Littlejohn LLP
1 Westferry Circus
Canary Wharf
London
E14 4HD
CohnReznick
1301 Avenue of the Americas
New York, NY 10019
Walbrook PR Limited
4 Lombard Street
London
EC3V 9HD
Tel: +44 (0)20 7933 8780
renalytix@walbrookpr.com
CapComm Partners
Peter DeNardo
Tel: +1 415-389-6400
Link Group
Central Square
29 Wellington Street
Leeds
LS1 4DL
Tel: 0371 664 0300
Email: shareholderenquiries@linkgroup.co.uk
Website: www.linkgroup.com
